Kineret (Anakinra)

What is Kineret?

Kineret is a Disease Modifying Anti Rheumatic Drug (DMARD), one of the new class called biologic response modifiers.

FDA approved:

November 2001

Average annual cost:

$11,000 annually

Brand Names and International Availability:

Kineret (US)

How does it work?

Designed specifically to treat inflammatory arthritis, it blocks a protein called Interleukin, a major player in the inflammatory process. By blocking IL-1, Kineret inhibits the inflammatory response in RA including pain.

Dosage:

Kineret comes in prefilled 1ml syringes, to be given daily.

How should I take it?

Kineret is injected subcutaneously daily. You may self inject after you are given proper instruction.

Contraindications:

Kineret is contraindicated in patients with known hypersensitivity to E.coli derived proteins.

Kineret has been associated with an increased risk of infection and should be used with caution in those with a history of serious infection.

Kineret has not been tested on pregnant mothers or nursing mothers and should only be used if clearly needed.

Drug Interactions:

No drug-drug interaction studies in human subjects have been conducted.

Possible side effects:

The most frequently reported side effect is injection site reaction. Other less serious side effects include headache, nausea and diarrhea.

More serious side effects that you should report right away include infection (sinusitis, fever, upper respiratory symptoms, unusual redness and swelling).

Signs of a possible allergic reaction are rash, swelling and difficulty breathing. These symptoms should be reported immediately.

Precautions & Special Notes:

You will be required to have frequent blood work while on this medication. It is very important that you keep all lab and doctor?s appointments.

This drug must be kept refrigerated until ready to use.

Please find out the proper method for needle disposal in your area.

For more information:

KineretRx.com
Arthritis @ About.com-Kineret

References:
Kineret Prescribing Information
Drug Firms Target Arthritis Treatment, LA Times